154 related articles for article (PubMed ID: 23555949)
1. Zoledronic acid produces combinatory anti-tumor effects with cisplatin on mesothelioma by increasing p53 expression levels.
Okamoto S; Jiang Y; Kawamura K; Shingyoji M; Fukamachi T; Tada Y; Takiguchi Y; Tatsumi K; Shimada H; Hiroshima K; Kobayashi H; Tagawa M
PLoS One; 2013; 8(3):e60297. PubMed ID: 23555949
[TBL] [Abstract][Full Text] [Related]
2. Combination of a third generation bisphosphonate and replication-competent adenoviruses augments the cytotoxicity on mesothelioma.
Jiang Y; Zhong B; Kawamura K; Morinaga T; Shingyoji M; Sekine I; Tada Y; Tatsumi K; Shimada H; Hiroshima K; Tagawa M
BMC Cancer; 2016 Jul; 16():455. PubMed ID: 27405588
[TBL] [Abstract][Full Text] [Related]
3. Zoledronic acid produces antitumor effects on mesothelioma through apoptosis and S-phase arrest in p53-independent and Ras prenylation-independent manners.
Okamoto S; Kawamura K; Li Q; Yamanaka M; Yang S; Fukamachi T; Tada Y; Tatsumi K; Shimada H; Hiroshima K; Kobayashi H; Tagawa M
J Thorac Oncol; 2012 May; 7(5):873-82. PubMed ID: 22481236
[TBL] [Abstract][Full Text] [Related]
4. Upregulated p53 expression activates apoptotic pathways in wild-type p53-bearing mesothelioma and enhances cytotoxicity of cisplatin and pemetrexed.
Li Q; Kawamura K; Yamanaka M; Okamoto S; Yang S; Yamauchi S; Fukamachi T; Kobayashi H; Tada Y; Takiguchi Y; Tatsumi K; Shimada H; Hiroshima K; Tagawa M
Cancer Gene Ther; 2012 Mar; 19(3):218-28. PubMed ID: 22223137
[TBL] [Abstract][Full Text] [Related]
5. Interferon-β produces synergistic combinatory anti-tumor effects with cisplatin or pemetrexed on mesothelioma cells.
Li Q; Kawamura K; Yang S; Okamoto S; Kobayashi H; Tada Y; Sekine I; Takiguchi Y; Shingyouji M; Tatsumi K; Shimada H; Hiroshima K; Tagawa M
PLoS One; 2013; 8(8):e72709. PubMed ID: 23977343
[TBL] [Abstract][Full Text] [Related]
6. p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acid.
Kuroda J; Kimura S; Segawa H; Sato K; Matsumoto S; Nogawa M; Yuasa T; Kobayashi Y; Yoshikawa T; Ottmann OG; Maekawa T
Cancer Sci; 2004 Feb; 95(2):186-92. PubMed ID: 14965371
[TBL] [Abstract][Full Text] [Related]
7. Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways.
Shimazu K; Tada Y; Morinaga T; Shingyoji M; Sekine I; Shimada H; Hiroshima K; Namiki T; Tatsumi K; Tagawa M
BMC Cancer; 2017 May; 17(1):309. PubMed ID: 28464864
[TBL] [Abstract][Full Text] [Related]
8. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents.
Koto K; Murata H; Kimura S; Horie N; Matsui T; Nishigaki Y; Ryu K; Sakabe T; Itoi M; Ashihara E; Maekawa T; Fushiki S; Kubo T
Oncol Rep; 2010 Jul; 24(1):233-9. PubMed ID: 20514467
[TBL] [Abstract][Full Text] [Related]
9. Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells.
Benassi MS; Chiechi A; Ponticelli F; Pazzaglia L; Gamberi G; Zanella L; Manara MC; Perego P; Ferrari S; Picci P
Cancer Lett; 2007 Jun; 250(2):194-205. PubMed ID: 17113707
[TBL] [Abstract][Full Text] [Related]
10. Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways.
Bruzzese F; Pucci B; Milone MR; Ciardiello C; Franco R; Chianese MI; Rocco M; Di Gennaro E; Leone A; Luciano A; Arra C; Santini D; Caraglia M; Budillon A
Cell Death Dis; 2013 Oct; 4(10):e878. PubMed ID: 24157872
[TBL] [Abstract][Full Text] [Related]
11. Combination of a p53-activating CP-31398 and an MDM2 or a FAK inhibitor produces growth suppressive effects in mesothelioma with wild-type p53 genotype.
Zhong B; Shingyoji M; Hanazono M; Nguyễn TT; Morinaga T; Tada Y; Shimada H; Hiroshima K; Tagawa M
Apoptosis; 2020 Aug; 25(7-8):535-547. PubMed ID: 32468177
[TBL] [Abstract][Full Text] [Related]
12. E1B-55 kDa-defective adenoviruses activate p53 in mesothelioma and enhance cytotoxicity of anticancer agents.
Yamanaka M; Tada Y; Kawamura K; Li Q; Okamoto S; Chai K; Yokoi S; Liang M; Fukamachi T; Kobayashi H; Yamaguchi N; Kitamura A; Shimada H; Hiroshima K; Takiguchi Y; Tatsumi K; Tagawa M
J Thorac Oncol; 2012 Dec; 7(12):1850-1857. PubMed ID: 23154556
[TBL] [Abstract][Full Text] [Related]
13. Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma.
Horie N; Murata H; Kimura S; Takeshita H; Sakabe T; Matsui T; Maekawa T; Kubo T; Fushiki S
Br J Cancer; 2007 Jan; 96(2):255-61. PubMed ID: 17242698
[TBL] [Abstract][Full Text] [Related]
14. Macrophages as potential targets for zoledronic acid outside the skeleton-evidence from in vitro and in vivo models.
Rogers TL; Wind N; Hughes R; Nutter F; Brown HK; Vasiliadou I; Ottewell PD; Holen I
Cell Oncol (Dordr); 2013 Dec; 36(6):505-14. PubMed ID: 24177992
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.
Ottewell PD; Mönkkönen H; Jones M; Lefley DV; Coleman RE; Holen I
J Natl Cancer Inst; 2008 Aug; 100(16):1167-78. PubMed ID: 18695136
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status.
Ory B; Blanchard F; Battaglia S; Gouin F; Rédini F; Heymann D
Mol Pharmacol; 2007 Jan; 71(1):333-43. PubMed ID: 17050806
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance and therapeutic implications of centromere protein F expression in human nasopharyngeal carcinoma.
Cao JY; Liu L; Chen SP; Zhang X; Mi YJ; Liu ZG; Li MZ; Zhang H; Qian CN; Shao JY; Fu LW; Xia YF; Zeng MS
Mol Cancer; 2010 Sep; 9():237. PubMed ID: 20828406
[TBL] [Abstract][Full Text] [Related]
18. Zoledronic acid induces apoptosis and S-phase arrest in mesothelioma through inhibiting Rab family proteins and topoisomerase II actions.
Okamoto S; Jiang Y; Kawamura K; Shingyoji M; Tada Y; Sekine I; Takiguchi Y; Tatsumi K; Kobayashi H; Shimada H; Hiroshima K; Tagawa M
Cell Death Dis; 2014 Nov; 5(11):e1517. PubMed ID: 25393473
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
Li YY; Chang JW; Chou WC; Liaw CC; Wang HM; Huang JS; Wang CH; Yeh KY
Lung Cancer; 2008 Feb; 59(2):180-91. PubMed ID: 17900752
[TBL] [Abstract][Full Text] [Related]
20. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
Caraglia M; Marra M; Leonetti C; Meo G; D'Alessandro AM; Baldi A; Santini D; Tonini G; Bertieri R; Zupi G; Budillon A; Abbruzzese A
J Cell Physiol; 2007 May; 211(2):533-43. PubMed ID: 17192846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
